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ABSTRACT
Background: Early-onset Group B Streptococcal (GBS) infection is an important cause of perinatal morbidity and mortality. 
Policy of active prevention by antepartum screening and treatment is not a popular practice in resource-constrained settings.
Objectives: This study determined the prevalence of asymptomatic GBS infection and antimicrobial sensitivity pattern. It 
also determined the outcome of Intrapartum antimicrobial prophylaxis (IAP).
Methodology: It was a prospective and longitudinal study done in Ahmadu Bello University Teaching Hospital, Zaria, between 
June 2014 and April 2015. Two hundred and twenty consenting pregnant women with gestational ages between 35 and 
37 completed weeks were participated in the study. Vagina and rectum were swabbed using different rayon swab sticks. 
Swabs were placed in Amies, nonnutritive transport medium. Bacteriological procedures to culture GBS and confirmation 
with biochemical tests and serological test were done. Antibiotic sensitivity pattern was determined. Participants who had 
GBS rectovaginal colonization had intrapartum antibiotic prophylaxis with penicillin G. All participants were followed up till 
to a week after birth.
Results: Out of the 220 pregnant participants, 19 (8.6%) had GBS rectovaginal colonization. Antibiotic sensitivity pattern 
revealed that GBS isolates were all sensitive to penicillin, ampicillin, and cefazolin while 4 (21.1%) were resistant to ceftriaxone 
and 6 (31.6%) were resistant to both erythromycin and clindamycin. None of the isolates were resistant to erythromycin and 
sensitive to clindamycin or vice versa. Of the 19 participants with GBS rectovaginal colonization, 2 (10.5%) delivered low 
birth weight baby, but there was no incidence of early-onset GBS disease.
Conclusion: The prevalence of GBS rectovaginal colonization in this study is similar to figures from other parts of the 
country. The GBS sensitivity pattern to penicillin was similar to those reported elsewhere. Fetal outcome following intrapartum 
antibiotic prophylaxis was good.
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Introduction
Group B streptococcus (GBS) is also known as Streptococcus 
agalactiae. GBS is a known cause of morbidity and mortality 
among neonates, infants, the geriatric age group, and 
immunosuppressed persons. GBS is a prominent veterinary 
pathogen because it can cause bovine mastitis in dairy cows. 
The species name “agalactiae” which means “no milk” alludes 
to this. GBS is a Gram-positive coccus,[1] an encapsulated 
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organism capable of producing severe disease. GBS is a cause 
of neonatal sepsis which can be classified as “early-onset” 
neonatal sepsis if it occurs within the 1st week of life and as 
“late-onset” neonatal sepsis if it occurs after the 1st week 
till the end of the neonatal period.[2] Maternal infection with 
GBS constitutes one of the leading causes of both early- and 
late-onset neonatal sepsis.[3] The major human reservoir of 
GBS is the vagina and the perianal regions. The bacteria are 
normally found in the vagina and lower intestine of 15%–40% 
of all healthy adult women.[4] Other sites frequently colonized 
are the oropharynx and the external auditory meatus of 
neonates. An association has been shown between GBS 
colonization of the vagina in pregnancy and a subsequent 
adverse outcome of the pregnancy.[5] The carrier rate in 
early pregnancy is less than at term.[6] Studies have observed 
higher GBS colonization in women toward the end of the 
gestational period.[5]
Early-onset perinatal GBS infection is a cause of early 
neonatal morbidity and mortality.[7] Some series have 
reported case-fatality ratios as high as 50%.[8] Estimates 
of the incidence of neonatal sepsis are mostly from 
single-facility studies and vary in their findings. In Nigeria, 
65 cases of neonatal sepsis per 1000 live births occurring in 
a referral hospital have been recorded.[9] A study in Malawi 
showed that early-onset neonatal sepsis caused by GBS alone 
was reported as 92 cases per 1000 live births.[10] Estimates 
of incidence of early-onset neonatal bacterial sepsis vary 
widely.
Clinical trials have demonstrated that administering 
intravenous antibiotics during labor to women at risk of 
vertically transmitting GBS to their newborns could prevent 
perinatal early-onset GBS disease in the 1st week of life.[11,12] 
A striking decline in perinatal early-onset GBS disease was 
observed to have coincided with increased prevention 
activities.[13] A further reduction occurred following the 
issuance of the recommendation for universal screening of 
pregnant women in 2002 by the center for disease control 
and prevention.[14]
Early-onset GBS disease remains a leading cause of illness 
and death among newborns.[15] Perinatal morbidity and 
mortality is a challenge in most African settings and infection 
is a foremost contributor. Routine screening and appropriate 
treatment of pregnant women for GBS infection would 
help decrease the rate of infection as a cause of perinatal 
morbidity and mortality. In the United States, before-active 
prevention was initiated an estimated 7500 cases of neonatal 
GBS occurred annually.[16] The purpose of this study is to 
determine the prevalence of asymptomatic GBS infection 
and antimicrobial sensitivity pattern among parturients at 
ABUTH, Zaria, Nigeria.
Methodology
The study was carried out in Ahmadu Bello University 
Teaching Hospital, Zaria, Kaduna state. It was a prospective 
and longitudinal study among pregnant women attending 
the antenatal clinic of ABUTH, Zaria.
It was carried out among pregnant women at a gestational 
age of 35–37 completed weeks that presented to the 
antenatal clinic and the delivery suite. Two hundred and 
twenty consenting pregnant women, fulfilling the inclusion 
and exclusion criteria as stated below, were enrolled for the 
study. The participants underwent microbiology evaluation 
for GBS rectovaginal colonization. Participants with positive 
GBS colonization had intrapartum treatment with penicillin 
G. The babies were followed up to a week postdelivery.
Inclusion criteria
Consenting pregnant women at the gestational age of 35–37 
completed weeks were included in the study.
Exclusion criteria
Pregnant women with abnormal vaginal discharge, women 
with symptoms and signs of urinary tract infection, pregnant 
women who received antibiotics within the past 1 month, 
and all pregnant women with risk factors for abnormal 
vaginal discharge and urinary tract infection such as 
immunocompromised women were excluded from the study.
Sample collection
Samples were collected in the outpatient setting by the 
researcher in the presence of a female chaperone. Pregnant 
women at 35–37 completed weeks’ gestation had the lower 
vagina, followed by the rectum swabbed with 2 different 
rayon swabs using aseptic technique. The swabs were 
placed in a nonnutritive transport medium (Amies transport 
medium) to maintain viability of GBS; this was labelled for 
client identification. None of the participants had a history 
suggestive of penicillin or cephalosporin allergy.
Sample processing
At the Medical Microbiology Laboratory of Ahmadu Bello 
University Teaching Hospital, the swabs were removed from 
the transport medium and inoculated into a selective broth 
medium, LIM broth (Todd-Hewitt broth supplemented with 
colistin 10 µg/ml and nalidixic acid 15 µg/ml). The inoculated 
selective broth was incubated for 24 h at 37°C in ambient air. 
The inoculated selective broth was subcultured onto sheep 
blood agar plate for 24 h, and the sheep blood agar plate 
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was then inspected to identify organisms suggestive of GBS 
by a narrow zone of beta-hemolysis.
Identification
If GBS was not identified after incubation for 24 h, the sheep 
blood agar plate was re-incubated and inspected at 48 h to 
identify suspected organisms. Suspected organisms were 
subjected to biochemical tests consisting of the catalase 
test and Christie–Atkins–Munch-Petersen (CAMP) test. 
Streptococcus grouping latex agglutination tests for GBS 
antigen detection were used for specific identification.
The catalase test was used to identify GBS. The catalase 
test was done by placing a drop of hydrogen peroxide on a 
microscope slide; an applicator stick was then used to obtain 
a sample of the growth from the agar plate; the obtained 
sample was mixed into the hydrogen peroxide drop on the 
microscope slide. If the mixture produces bubbles or froth, 
the isolated organism was ascribed to be catalase positive. 
If no bubbles or froth is formed, the organism will be said to 
be catalase negative. GBS is catalase-negative.
The CAMP test is an acronym for the three researchers 
“Christie–Atkins–Munch-Petersen” who discovered the 
lytic phenomenon between Staphylococcus aureus and GBS. 
The CAMP test is based on the principle that colonies of 
Streptococcus were only surrounded by zones of complete 
hemolysis when they were growing on blood agar plate in 
proximity to colonies of β-hemolytic Staphylococcus, due to 
the formation of CAMP factor by GBS which enlarges the 
area of hemolysis formed by β-hemolysin from S. aureus. 
Other organisms apart from GBS fail to exhibit this enhanced 
hemolysis when grown near colonies of β-hemolytic 
Staphylococcus.
Streptococcus grouping latex agglutination tests for GBS 
antigen detection were used for serological identification. 
A Streptococcus latex group kit was used for serotyping. The 
kit has the capability to identify groups A, B, C, D, F, and G 
streptococci which are the most prevalent streptococci. The 
kit consists of latex particles covered with streptococcal 
group antiserum for groups A, B, C, D, F, and G streptococci. 
Accompanying this antiserum is extraction reagents, 
reaction cards, and mixing sticks. The test was conducted 
by mixing on the reaction card, the group antiserum with 
a specimen obtained from the selective broth which had 
been inoculated and incubated for 24 h at 37°C in ambient 
air. If there was no reaction or the reaction is indistinct, the 
extraction reagent was added. Agglutination was observed 
within 30 s for a positive reaction, while for a negative 
reaction, there was no agglutination within 30 s of the test
Antibiotic susceptibility testing
The modified Kirby-Bauer standardized disc diffusion testing 
was done. It entails using a sterile cotton swab to make a 
suspension from a 24-h growth of the organism in saline to 
match a 0.5 McFarland turbidity standard. Within 15 min of 
adjusting the turbidity, a sterile cotton swab was dipped into 
the adjusted suspension. The swab was rotated several times 
and pressed firmly on the inside wall of the tube above the 
fluid level. The swab was then be used to inoculate the entire 
surface of a Mueller-Hinton sheep blood agar (MHA) plate 
while rotating the plate at an angle of 60° three times. After 
10 mins of inoculating, the plate sterile forceps were used to 
place penicillin G (10 µg), ampicillin, (10 µg), cefazolin (30 µg), 
cefotaxime (30 µg), ceftriaxone (30 µg), clindamycin (2 µg), 
and erythromycin (15 µg). The MHA plate was then incubated 
at 35°C in 5% CO2-enriched atmosphere for 24 h, after which 
zones of growth inhibition around the disks are identified. 
The presence of zones of growth inhibition is synonymous 
with susceptibility, and the absence of zones of growth 
inhibition is synonymous with resistance.
For isolates showing resistance to erythromycin but 
susceptibility to clindamycin, a double-disk diffusion 
test (D-test) was conducted on them because of the risk 
of inducible clindamycin resistance. Such strains were 
tested (D-test) for inducible clindamycin resistance by 
placing an erythromycin, and clindamycin disks 20 mm 
apart on a MHA plate inoculated with the strain in question. 
After overnight incubation, the plates were observed for a 
blunted zone of growth inhibition around the clindamycin 
disk. If the zone was not blunted, the isolate would be 
reported as susceptible to clindamycin. If there was a 
blunted zone of growth or a D-shape is formed around 
the clindamycin disk, the isolate was reported either as 
resistant or as susceptible with a comment that resistance 
may develop during clindamycin therapy. The diameter 
of the zone of inhibition was measured using a caliper 
and interpreted according to Clinical and Laboratory 
Standards Institute 2011 guidelines for Streptococcus 
species other than Streptococcus pneumoniae (breakpoints: 
clindamycin: ≥19 mm = susceptible, 16–18 = intermediate, 
and ≤15 = resistant; erythromycin: ≥21 mm = susceptible, 
16–20 = intermediate, and ≤15 = resistant).
Results
A total of two hundred and twenty pregnant women who 
fulfilled the inclusion criteria between the gestational ages 
of 35–37 completed weeks and who consented to participate 
in the study were recruited into the study. There was a 100% 
participation.
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The sociodemographic characteristics of the participants 
showed that they were aged between 18 and 42 years 
with a mean of 27.4 ± 5.3 years. The age distribution 
of the participants showed that 1.4% were less 20 years, 
28.6% were 20–24 years, 44.5% were 25–29 years, 12.7% 
were 30–34 years, 9.1% were 35–39 years, and 3.6% 
were ≥40 years. Twelve participants (5.5%) were nulliparous, 
37 (16.7%) were primiparous, 4 (1.8%) were grand multiparous, 
and 167 (76%) had parity ranging from 2 to 4.
Majority, i.e., 42.7%, had pregnancies at a gestational age of 
37 weeks, 39.5% of the participants were at a gestational age 
of 36–37 weeks, and 17.7% had pregnancies at a gestational 
age of 35–36 weeks.
All the participants were married, 9.1% were in the upper 
socioeconomic class, 31.8% were in the middle socioeconomic 
class, while 59.1% were in the lower socioeconomic class.
All the two hundred and twenty rectovaginal cultures 
yielded a growth of microorganisms. Rectovaginal cultures 
isolated GBS in 19 (8.6%) of the specimens obtained while 
201 (91.4%) rectovaginal cultures did not isolate GBS. 
Serological/antigen testing of the cultures was positive for 
GBS in 19 (8.6%) of the specimens and negative for GBS in 
the remaining 201 (91.4%). All the 19 (8.6%) rectovaginal 
cultures in which GBS was isolated had a positive serological 
test for GBS [Table 1].
In 19 participants with positive GBS isolates, ages 20–24 years 
constituted 36.8% while ages 25–29 years constituted 
57.9% and ages ≥40 years constituted 5.3%. There was no 
statistically significant association between maternal age 
and GBS rectovaginal colonization (Fisher’s exact = 6.224, 
P = 0.229) [Table 1].
Of the 19 (8.6%) with GBS rectovaginal colonization, 52.6% 
were nulliparous, 26.3% were primiparous, 15.9% were 
multiparous, while 5.3% were grand multiparous. There was 
a statistically significant association between parity and 
GBS rectovaginal colonization (Fisher’s exact = 53.289, 
P = 0.001) [Table 1].
Gestational age of the 19 participants with GBS 
colonization showed that 57.8% were at a gestational 
age of 37 weeks while 21.1% were at a gestational age 
of 35–36 weeks’ gestation and another 21.1% were 
at a gestational age of 36–37 weeks. There was no 
statistically significant association between gestational 
age and GBS rectovaginal colonization (χ2 = 3.048, 
P = 0.218) [Table 1].
In relation to social class, 10.0% of the women who were in the 
upper socioeconomic class had GBS rectovaginal colonization, 
15.6% were in the upper middle class, 5.3% in the lower 
middle class, while 14.3% were in the lower socioeconomic 
class. There was no statistically significant association 
between socioeconomic class and GBS rectovaginal 
colonization (Fisher’s exact = 4.720, P = 0.299) [Table 1].
Among the 201 participants who were negative for GBS 
isolates, 7.9% of babies born were low birth weight as against 
10.5% of low birth weight babies born to 19 participants with 
GBS rectovaginal colonization [Table 2].
Table 1: Association between independent variables and 
presence or absence of group B streptococci
Independent Variable GBS‑positive GBS‑negative Test statistic
Age group (years)
<20 0 3 (100) Fisher’s 
exact=6.224
P=0.229
20‑24 7 (11.1) 56 (88.9)
25‑29 11 (11.2) 87 (88.8)
30‑34 0 (0) 28 (100)
35‑39 0 (0) 20 (100)
>40 1 (12.5) 7 (87.5)
Parity
0 10 (83.3) 2 (16.7) Fisher’s 
exact=53.289
P=0.001*
1 5 (13.5) 32 (86.5)
2 1 (1.2) 83 (98.8)
3 2 (2.9) 67 (97.1)
4 0 144 (100)
>4 1 (25.0) 3 (75.0)
Gestational age (weeks)
35 4 (10.3) 35 (89.7) χ2=3.048
P=0.21836 4 (4.6) 83 (95.4)
37 11 (11.7) 83 (88.3)
Socioeconomic class
1 2 (10.0) 18 (90.0) Fisher’s 
exact=4.720
P=0.299
2 5 (15.6) 27 (84.4)
3 2 (5.3) 36 (94.7)
4 8 (10.7) 67 (89.3)
5 2 (3.6) 53 (96.4)
*Statistically significant association. GBS ‑ Group B streptococcus
Table 2: Labor and delivery outcomes




Estimated gestational age (weeks)
>40 17 (89.5) 181 (90.1)
<40 2 (10.5) 20 (9.9)
Membrane. rupture length (h)
<18 19 (100) 201 (100)
>18 0 0
Type of delivery
Vaginal 17 (89.5) 183 (91.0)
Cesarean section 2 (10.5) 18 (9.0)
GBS ‑ Group B streptococcus
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All 19 participants who had GBS rectovaginal colonization 
in pregnancy had intrapartum antibiotic prophylaxis with 
intravenous penicillin G. All babies born to these women did 
not show clinical features of sepsis during the 24-h mandatory 
hospital stay. These babies were followed up during the 
1st week of life; during this period, none of the babies had 
fever, difficulty with suckling, or breathing difficulties.
The antibiotic sensitivity pattern revealed that the GBS 
isolates were all sensitive to penicillin, ampicillin, and 
cefazolin. Six (31.6%) of GBS isolates were resistant to both 
erythromycin and clindamycin. None of the isolates were 
resistant to erythromycin and sensitive to clindamycin or 
vice versa.
Comment
There was a statistically significant association between 
parity and presence of GBS while age group, gestational age, 
and socioeconomic class showed no statistically significant 
association with GBS.
Discussion
GBS is a leading cause of morbidity and mortality among 
neonates. Screening for rectovaginal colonization among 
pregnant women is not a routine practice at ABUTH, Zaria. This 
study showed the prevalence of GBS rectovaginal colonization 
among pregnant women attending ANC at ABUTH to be 8.6%. 
A study in Nigeria by Nwachukwu[17] on genital colonization 
with GBS at 36–40 weeks’ gestation done in Calabar reported 
a prevalence rate of 9.0%, which is similar to the prevalence 
obtained in this study. In contrast, a high prevalence of 11.3% 
was obtained from the study by Onipede et al.[18] at Ile-Ife. The 
variation between the Ile-Ife study and this study could possibly 
be due to variation in maternal colonization from place to 
place, and the wider gestation age ranges of 35–40 weeks 
different to 35 weeks to 37 completed weeks used in this 
study. Other factors that may have contributed to this variation 
include ethnic and genetic factors.
In this study, there was no significant statistical association 
between GBS rectovaginal colonization and the age of the 
participants. However, a study in Ibadan[19] documented an 
increase in GBS rectovaginal colonization with increasing 
maternal age so also did the study in Calabar[17] and Ile-Ife;[18] 
however, a study from Malawi[20] reported a decrease in GBS 
rectovaginal colonization with increasing maternal age.
This study showed that there was a statistically significant 
association between parity and rectovaginal colonization 
among pregnant women attending ANC at ABUTH, 
P = 0.001. The prevalence of rectovaginal colonization 
decreased with increasing parity. This finding is in 
corroboration with the statement that some women with 
GBS colonization during pregnancy will be colonized 
during subsequent pregnancy; however, a substantial 
proportion will not.[21,22]
This study showed no statistically significant association 
between GBS rectovaginal colonization and the socioeconomic 
status of the participant similar to finding by Zusman et al. in 
Brazil.[23] The Multicenter Vaginal Infection and Prematurity 
Study group in the United States also reported a weak 
association between GBS colonization and socioeconomic 
standing.[24]
In this study, all GBS isolates showed a susceptibility to 
penicillin which is the common agent used for intrapartum 
antibiotic prophylaxis. The study done in Calabar[17] showed 
that GBS organisms isolated were all susceptible in vitro to 
penicillin; this was consistent with observations by other 
investigators.[25] However, in Ile-Ife, there was a high level of 
resistance of GBS isolates to ampicillin and penicillin. Factors 
attributed to this high level of resistance of GBS isolates to 
ampicillin and penicillin included the ease of procurement 
of over-the-counter antibiotics in developing countries 
resulting in inappropriate use and abuse of these antibiotics 
consequently resulting into drug-resistant strains of GBS. In 
this study, 6 (31.6%) of the GBS isolates were resistant to both 
erythromycin and clindamycin.
Intrapartum antibiotic prophylaxis (IAP) using intravenous 
penicillin G was administered to participants who had GBS 
rectovaginal colonization, and none of the babies had fever, 
difficulty in breathing, or difficulty in the 1st week of life. 
Intrapartum antibiotic prophylaxis (IAP) has been shown 
to reduce vertical transmission of GBS, as measured by 
infant colonization[11] or by protection against early-onset 
disease.[12,13] With the use of intrapartum antibiotic prophylaxis, 
observational studies found an effectiveness of 86%–89% 
in the prevention of early-onset disease among infants 
born to women with GBS colonization.[26,27] In conclusion, 
this study demonstrated that the prevalence of GBS 
rectovaginal colonization of 8.6%. Parity was found to have 
a significant statistical association with GBS rectovaginal 
colonization among participants in this study; there was an 
inversely proportionate relationship between parity and GBS 
rectovaginal colonization in this study. This study showed that 
GBS was susceptible in vitro to penicillin, thus making penicillin 
the first-line choice in women who are not allergic to penicillin.
This study showed a high prevalence of GBS rectovaginal 
colonization. Public enlightenment of the general population 
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on screening for GBS rectovaginal colonization in pregnant 
women and its relationship with prevention of early-onset 
neonatal sepsis is suggested. Detection of GBS rectovaginal 
colonization through routine screening of all antenatal 
patients at 35–37 weeks is advocated. Administration 
of intrapartum antibiotics prophylaxis during labor is 
recommended for all pregnant women who screened positive 
for GBS rectovaginal colonization. The aforementioned 
suggestions may be appropriate in resource-constrained 
medical settings in most African countries. However, in 
some developed countries like the United Kingdom, routine 
bacteriological screening is not advocated in pregnancy 
except the woman has an increased risk of having a baby 
with early-onset GBS disease.[28]
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